News & Events

Breakfast & Biotech with Biocytogen

Biocytogen eagerly invites fellow industrial partners and colleagues to join us for a Biotech and Breakfast session at the MassBio Hub. About this event Therapeutic…

Read more
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy

Beijing and Guangzhou, China, September 15, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co.,…

Read more
Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen

Our webinar “Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen" was live on Sep 29, 2022 at 1PM EDT. An understanding of the exposure-response…

Read more
mouse-on-top-of-medicine
Research Impact: Custom Biocytogen mouse models used to identify critical mediator of inflammation-driven metastases

By John Charpentier, Ph.D. September 7, 2022 While metastases are ultimately responsible for the large majority of cancer deaths, most oncology drugs in development target…

Read more
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Beijing, China, September 1, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the company’s official listing on the Main Board of the…

Read more
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Beijing, China and San Diego, CA, August 29, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced…

Read more
Biocytogen Expands Partnership with Merck

Beijing, China and Darmstadt, Germany, August 25, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered into a global licensing agreement with Merck for the…

Read more
2022 Popular Mouse Models and Cell Lines

Biocytogen’s advanced genome editing technologies have been leveraged by our own development scientists to create hundreds of animal and cell models used in biomedical research…

Read more
First Half of 2022 Publications Highlight

Our off-the-shelf and custom animal and cell models are advancing cutting-edge biomedical research every day. One measure of this impact is how often they appear…

Read more
Webinar: Preclinical Models to Investigate NK Cell-Targeted Immunotherapies

Our webinar “Preclinical Models to Investigate NK Cell-Targeted Immunotherapies" was live on Aug 31, 2022 at 1PM EDT. In this webinar, we  Reviewed the mechanisms…

Read more
Back to top